{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-25-021445","form_type":"8-K","ticker":"MBRX","cik":"0001659617","company_name":"Moleculin Biotech, Inc.","filed_at":"2025-06-27T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.241352+00:00","generated_at":"2026-05-18T16:01:45.386505+00:00","sec_items":["3.01"],"event_type":"regulatory","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Moleculin Biotech receives Nasdaq deficiency notice; 180 days to regain $1.00 bid price","bullets":["Received Nasdaq deficiency letter on June 27, 2025 for bid price below $1.00 for 30 consecutive days.","Must close at $1.00 or more for 10 consecutive days by December 24, 2025 to regain compliance.","Company may consider a reverse stock split to cure the deficiency.","If not compliant by Dec 24, may be eligible for second 180-day period if meeting other standards.","Failure to regain compliance may lead to delisting from Nasdaq Capital Market."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-25-021445","json":"https://secwatch.observer/filing/0001437749-25-021445.json","markdown":"https://secwatch.observer/filing/0001437749-25-021445.md","text":"https://secwatch.observer/filing/0001437749-25-021445.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1659617/000143774925021445/0001437749-25-021445-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1659617/000143774925021445/mbrx20250627_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-18T16:01:45.386505+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"c3e0fda321e99030bb14fd7d9f41afc28a0d0a86","claim":"Moleculin Biotech, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).","evidence_excerpt":"June 27, 2025, Moleculin Biotech, Inc. (the “Company”) received a deficiency letter from the Listing Qualifications Department (the “Staff”) of the Nasdaq Stock Market (“Nasdaq”) notifying the Company that for the last 30 consecutive business days the bid price for the Company’s common stock had closed below the minimum $1.00 per share requirement for continued inclusion on the Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Rule”). The deficiency letter does not result in the immediate delisting of the Company’s common stock from the Nasdaq Capital Market. In","evidence_source":"SEC 8-K Item 3.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1659617/000143774925021445/0001437749-25-021445-index.htm","confidence":0.95,"family_label":"Listing & Compliance Notices","details":[{"label":"Exchange","value":"nasdaq"},{"label":"Notice","value":"deficiency notice"},{"label":"Deficiency","value":"minimum bid price"},{"label":"Rules","value":"5550(a)(2), 5810(c)(3)(A)"}],"fact_type":"exchange_compliance_notice"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}